Karyopharm's Selinexor Fails Primary Endpoint in Endometrial Cancer Trial
Event summary
- Karyopharm's Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer missed its primary endpoint of progression-free survival (PFS).
- The selinexor arm showed a 5.3-month improvement in median PFS over placebo, but the result was not statistically significant (p-value=0.0791).
- Karyopharm will reduce investment in endometrial cancer and focus on myelofibrosis and multiple myeloma programs.
- Topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial for myelofibrosis is expected in the second half of 2026.
The big picture
Karyopharm's failure to meet the primary endpoint in endometrial cancer highlights the challenges of developing targeted therapies for specific patient populations. The company's strategic shift towards myelofibrosis and multiple myeloma aligns with its established commercial infrastructure and approved indications for selinexor. The upcoming milestones in these areas will be critical in determining Karyopharm's long-term growth prospects.
What we're watching
- Pipeline Prioritization
- Whether Karyopharm can successfully pivot resources from endometrial cancer to myelofibrosis and multiple myeloma programs.
- Regulatory Milestones
- The timing of the sNDA submission for selinexor in myelofibrosis and its potential inclusion in compendia guidelines.
- Clinical Data Impact
- How the upcoming topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial will influence investor sentiment.
Related topics